Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

<p>Abstract</p> <p>Background</p> <p>The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP...

Descripció completa

Dades bibliogràfiques

Autors principals:	Nakano Kazuhiko, Ohta Shigeyuki, Komatsu Kenji, Kubo Taro, Nukui Akinori, Suzuki Kazumi, Kurokawa Shinsuke, Kobayashi Minoru, Morita Tatsuo
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2012-02-01
Col·lecció:	BMC Urology
Accés en línia:	http://www.biomedcentral.com/1471-2490/12/3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!